AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$KURA

WILSON TROY EDWARD purchased $1.2M of KURA (indirect holdings)

WILSON TROY EDWARD (President and CEO) purchased 100,000 indirectly-held shares of Kura Oncology, Inc. (KURA) at $12.39 ($1.24M total) on 2026-08-24.

Original reporting
SEC EDGAR · WILSON TROY EDWARD
Published Aug 24, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 9:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KURA
Bullish
medium confidence
Mentioned
$KURA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KURABullishMed
01

Why it matters

The purchase adds credibility to management's outlook, possibly encouraging short‑term buying pressure.

02

Market read

Insider buy by the CEO is a notable event for a micro‑cap biotech, offering a modest trading edge.

03

What to watch

Potential upcoming clinical trial data that prompted the purchase is not disclosed.

Relevance 7/10Novelty 7/10Timing: filing released today

Background

SEC Form 4 filing discloses insider transactions; such filings are primary sources of new information.

Company-level read

Ticker impact

$KURABullishMedium confidence
Context

CEO Troy Edward Wilson bought 100,000 shares for $1.239M, increasing his stake to 479,194 shares.

Expected impact

Potential modest price lift in the next few days as investors note the buy.

Evidence & confidence

A $1.2M open‑market purchase by the CEO is a material insider transaction for a micro‑cap biotech, often viewed as a bullish signal.

Market effects

Sector

May lift sentiment in the oncology biotech sector as insider confidence is noted.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche biotech investors.

Counterpoint

What could challenge this read

Insider buying could be a routine portfolio rebalancing, not a strong catalyst.

Key entities

  • Company
    Kura Oncology, Inc.

    Biotech firm developing oncology therapies, ticker KURA.

  • Executive
    Troy Edward Wilson

    President and CEO of Kura Oncology.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KURA insider trading history →

Related articles

AUG 19
$KURAHighAI 8/10

Kura Oncology (KURA) Q2 2026 Earnings Call Transcript

Kura Oncology (KURA) reported Q2 2026 earnings, with KOMZIFTI net product revenue up 57% QoQ to $9.1M. New patient starts increased 35% to 115, capturing majority market share in a specific leukemia segment. Total prescriptions rose 59% to 250. Cash decreased to $519M from $667.2M. Collaboration revenue guidance set at $45M-$55M for 2026. Net loss was $68.3M, up from $66.1M YoY. Clinical data showed strong results for ziftomenib and darlifarnib. Management expects pivotal trial results in 2028.

fool.com3 min
AUG 12
$KURAMed

Kura Oncology, Inc. (KURA): Results of Operations and Financial Condition

Kura Oncology, Inc. (KURA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kura-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Kura Oncology Reports SECOND Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q – – KOMZIFTI ® achi

SEC EDGAR 8-K6 min
MAY 29
$KURAMedAI 9/10

Kura Oncology Touts KOMZIFTI Launch Momentum, $3B Frontline AML Opportunity

Kura Oncology (NASDAQ:KURA) said at TD Cowen’s Oncology Innovation Summit it is building momentum for its newly approved AML therapy KOMZIFTI (ziftomenib) in relapsed/refractory NPM1-mutant AML, citing 85 new patient starts and 157 prescriptions in Q1 and $5.8M revenue. Executives also highlighted darlifarnib+adagrasib solid-tumor response data and updated KOMET-007 results ahead of ASCO and EHA.

dailypolitical.com7 min